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Background: Neurodegenerative diseases (NDs) are characterized by the progressive loss of neurons in the human
brain. Although the majority of NDs are sporadic, evidence is accumulating that they have a strong genetic
component. Therefore, significant efforts have been made in recent years to not only identify disease-causing genes
but also genes that modify the severity of NDs, so-called genetic modifiers. To date there exists no compendium
that lists and cross-links genetic modifiers of different NDs.
Description: In order to address this need, we present NeuroGeM, the first comprehensive knowledgebase providing
integrated information on genetic modifiers of nine different NDs in the model organisms D. melanogaster, C. elegans,
and S. cerevisiae. NeuroGeM cross-links curated genetic modifier information from the different NDs and provides details
on experimental conditions used for modifier identification, functional annotations, links to homologous proteins and
color-coded protein-protein interaction networks to visualize modifier interactions. We demonstrate how this database
can be used to generate new understanding through meta-analysis. For instance, we reveal that the Drosophila genes
DnaJ-1, thread, Atx2, and mub are generic modifiers that affect multiple if not all NDs.
Conclusion: As the first compendium of genetic modifiers, NeuroGeM will assist experimental and computational
scientists in their search for the pathophysiological mechanisms underlying NDs. http://chibi.ubc.ca/neurogem.
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disease, Huntington’s diseaseBackground
Intracellular protein aggregation is a feature of many
late-onset neurodegenerative diseases (NDs), also called
proteinopathies. These include Alzheimer’s disease (AD),
Parkinson’s disease (PD), and nine polyglutamine expan-
sion diseases exemplified by Huntington’s disease (HD).
The pathophysiology of NDs is very complex, which is
one of the reasons why there are no effective strategies
that slow or prevent neurodegeneration.
In recent years, significant efforts have been made to
identify genes that modify the severity of NDs. Altering
the activities of these genetic modifier genes on their
own may not result in obvious phenotypes in the ab-
sence of the conditioning (neurodegeneration-causing)
mutation. However, the identified genetic modifiers* Correspondence: gsponer@chibi.ubc.ca
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reproduction in any medium, provided the orallow the characterization of biological pathways that
modulate the disease and, in some cases, discovery of
tractable therapeutic targets. The identification of genetic
modifiers has been facilitated due to the development of
in vivo models of different proteinopathies in organisms
such as D. melanogaster and C. elegans [1-3]. Moreover,
genome-wide screens for genetic modifiers have become
possible because of high-throughput technologies such as
RNA interference [4] or public availability of various
transgenic stocks covering most genes such as fly stocks
with P-element insertion mutations [5].
Nevertheless, due to the complex nature of the patho-
logical processes underlying proteinopathies, there are large
inconsistences in the collected data. Even more import-
antly, data alone without knowledge or integration into
existing databases is bound to remain inaccessible and thus
cannot be utilized by the broad scientific community. An
integrated database of genetic modifiers of NDs would as-
sist computational and experimental scientists alike inThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1755-8794/6/52improving their approaches to discover what is common to
and distinct for different proteinopathies.
In order to address this need, we assembled the first
comprehensive database of genetic modifiers in NDs.
NeuroGeM (‘neurodegenerative disease genetic modifiers
database’) catalogues and cross-links genetic modifiers of
9 different NDs in three different model organisms, and
associates them with information on protein function and
other annotations. NeuroGeM contains detailed informa-
tion on the experimental conditions in which the modifiers
were identified, displays the protein-protein interaction
sub-network around modifiers, and provides search and
display tools to deduce testable hypotheses. Furthermore,
in order to demonstrate the broad applicability of the data




NeuroGeM is a comprehensive collection of literature
data on genetic modifiers of NDs and associated genetic
information from a variety of databases (Figure 1). The
ND models include AD subclassified as ADAβ (amyloid-Figure 1 The contents of NeuroGeM. NeuroGeM is a comprehensive colle
and S. cerevisiae. In order to provide comprehensive information on genetic m
(FlyBase, WormBase, SGD, EBML, HGNC, and MGI), the protein interaction data
(HomoloGene and InParanoid). The statistics of the data currently available in
listed in Table 2.beta models) and ADTau (tau models), HD, PD, Spino-
cerebellar ataxia type 1, 3 and 7 (SCA1, SCA3, SCA7),
Amyotrophic lateral sclerosis (ALS) and generic polyQ-
induced disease in D. melanogaster, C. elegans, and
S. cerevisiae. At the time of data compilation, all known
high-throughput (HT) screens for modifiers carried out in
the model organisms and a handful of low-throughput
(LT) experimental results were included. Overall, Neuro-
GeM contains 87,864 experimental records (3,618 for
modifiers and 84,246 for non-modifiers) from the 9 differ-
ent disease models in the three different species (Table 1).
Importantly, we continually update the knowledgebase
with newly published results. In addition, users can sub-
mit their own data upon request of a login and the
uploaded data will be made accessible to all users after
curation (see Additional file 1).
In order to provide comprehensive information on
genetic modifiers, we integrated relevant data from other
sources into NeuroGeM. All entries in NeuroGeM con-
tain information on gene function/annotations and are
accompanied by direct links to the relevant information
on FlyBase for D. melanogaster (ver Feb 2012) [6],
WormBase for C. elegans (ver WS230) [7] and SGD forction of genetic modifiers of ND models in D. melanogaster, C. elegans,
odifiers, NeuroGeM also integrates information from genome databases
base STRING, GeneOntology, and homologous gene databases
NeuroGeM is shown in Table 1, and all terms used in the database are
Table 1 Statistics of genetic modifiers in NeuroGeM
Species Disease
models
Experimental records Modifiers1 Gene
coverage2 (%)Positive records Negative records Enhancers Suppressors Non-modifiers
D. melanogaster ADTau 144 571 65 60 549 4.89
ADAβ 61 6062 25 22 6059 44.43
PD 1 - - 1 - 0.01
HD 1260 8142 130 90 7732 57.82
SCA1 66 24 16 21 21 0.42
SCA3 623 52 55 520 49 4.54
SCA7 14 19 8 5 18 0.23
PolyQ 22 44 7 10 43 0.44
C. elegans ADTau 75 15909 - 75 15899 97.86
ADAβ 6 - 1 5 - 0.04
HD 22 2 1 17 2 0.12
PD 290 18121 - 268 15767 98.24
ALS 168 15909 88 80 15817 97.92
PolyQ 459 40 152 195 20 2.11
S. cerevisiae ADAβ 106 5262 18 23 5248 78.83
HD 82 9422 28 54 4670 70.83
PD 216 4699 22 181 4577 71.26
PolyQ 1 - - 1 - 0.01
1Certain genes have been identified independently as both an enhancer and suppressor under different experimental conditions.
2With respect to the protein coding genes.
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entered in NeuroGeM contains an ID that is identical to
the primary ID of the gene in its respective genome
database (FlyBase, WormBase, or SGD). These IDs will
allow users to easily access other databases and avoid
the effort required for ID conversion. NeuroGeM re-
cords have a link to the PubMed entry of the original
study from which the records stem.
As protein-protein interaction networks allow identifi-
cation of functionally associated proteins or important
functional clusters [9,10], NeuroGeM visualizes the pro-
tein interaction sub-network around a queried gene;
each protein node in the network is color-coded accord-
ing to the available experimental results deposited in
NeuroGeM. For this feature, NeuroGeM utilizes the pro-
tein interaction data from STRING (ver 9.05) [11]. In
order to facilitate the identification of genetic modifiers
with the same function or involved in the same process,
NeuroGeM provides an ontology-based search functional-
ity that searches for genes by GeneOntology (GO) annota-
tions and the hierarchical structure of GO terms [12].
As users might be interested in finding homologs of the
genetic modifiers entered in NeuroGeM, we also inte-
grated homologous gene data from NCBI HomoloGene
(build 65) [13] and InParanoid (ver7) [14,15]. Orthologs
are defined as genes in different species that have evolved
from a common ancestral gene, while paralogs are genesrelated by duplication within the same species that often
have different functions. Homologs are either paralogs or
orthologs (for details see NCBI HomoloGene (build 65)
[13] and InParanoid (ver7) [14,15]). The homology data
covers not only the three model organisms but also
H. sapiens and M. musculus, though no modifiers from
these organisms are deposited in NeuroGeM yet. Cross-
linking genes via homology should facilitate the expan-
sion of modifier studies in other organisms; for instance,
confirmation of important modifiers in higher organ-
isms. Gene information, GO annotations and protein
interaction data for human and mouse genes were also
integrated to help users search for modifiers that are
homologous to human and mouse genes of interest.
(source: EMBL Rel 68 [16], HGNC downloaded in Jan
2013 [17]; EMBL Rel 68 [18]; and MGI downloaded in
Dec 2012 [19]). As detailed information on genes and
proteins is frequently updated in their source databases,
NeuroGeM also provides links to those databases when
available.
Database implementation
The database was implemented with a web interface
compatible with common web browsers to provide ac-
cess to researchers. The data is stored in a relational
database using a MySQL 5.0.59 server. Data processing
and HTML generation for displaying information are
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nology are used to improve search functions. Cytoscape-
Web [20] is employed to visualize protein-protein
interaction networks. The current database is running
on Redhat Linux 5.6 with an Apache server 2.2.3. All the
data in NeuroGeM can be downloaded as plain text files.
Utility and discussion
NeuroGeM allows users to access the integrated data in
three different ways: (i) a categorical search, (ii) a key-
word search, and (iii) an ontology-based search. All
search methods take users first to a list of publications
or a list of genes that fit the search criteria, from which
users can select a gene of interest and consult its modifier
information page. Figures 2 and 3 and Additional file 2:
Figures S1 and Additional file 3: Figure S2 illustrate the
three ways to search genetic modifiers in NeuroGeM and
show detailed information on genetic modifiers provided
by NeuroGeM.
Categorical search for studies that identified modifiers
On the front page of the NeuroGeM web site, research re-
sults are organized according to disease and model-
organism categories: studies that identified modifiers were
categorized according to model organism (n = 3) and dis-
eases (n = 9 including two AD subtypes) (Additional file 2:
Figure S1). Clicking on an organism icon or disease-
specific icon directs the user to a list of publications that
belong to that category. Clicking on a pie chart at the
intersection of a specific model organism and disease type
directs the user to a list of publications that searched forFigure 2 Search to access information on genetic modifiers in NeuroG
of a specific genetic modifier. Other search methods are available in Additi
S2 (ontology-based search). The genetic modifier information page include
(b) general information on the gene with links to relevant databases, and (
Details about experimental parameters and results are also shown (Figure 3
genetic information and experimental details of homologous genes.modifiers in the corresponding disease model and organ-
ism. Clicking on a specific publication then directs the
user to a list of genes that have been tested in that study.
For instance, clicking on the pie chart at the intersection
of D. melanogaster and HD (Additional file 2: Figure S1)
lists 24 publications in which genetic modifiers of HD
have been identified in D. melanogaster. Clicking on the
PubMed ID 17984172 will open a web page that lists the
26 genes that have been examined in this specific study
and provides a summary of the experimental records
deposited in NeuroGeM for each of these 26 genes (see
below for the detailed explanation of the record sum-
mary). Clicking on the gene name Nup44A will then direct
the user to the genetic modifier information page of
Nup44A, which contains the details of the results of dif-
ferent genetic modifier screens for this gene as well as
additional information that is discussed in further detail in
the “Genetic modifier information” section below.
Keyword-based search for specific genes
NeuroGeM also provides different search methods from
a unified search box (Figure 2). As a user starts typing
letters in the search box, NeuroGeM suggests matching
keywords (gene name, synonyms, IDs, GO terms, etc.). If
the user selects one of the suggestions, NeuroGeM will
open this gene’s modifier information page (Figure 2, red
arrow). If the user presses the ‘Search’ button instead,
NeuroGeM will list all genes that contain the keyword
in their names, synonyms, or IDs. Then, the user can
open a specific genetic information page by clicking on
one of the listed genes (Figure 2, blue arrow). ForeM. This figure illustrates a keyword-based search to get information
onal file 2: Figure S1 (categorical search) and Additional file 3: Figure
s (a) a report summary of experimental records entered in NeuroGeM,
c) the protein-protein interaction sub-network around this gene.
). The homologous genes section (not shown in this figure) lists
Figure 3 Details of the experiments that identified the genetic modifiers. This section of the genetic modifier information page includes
the detailed results of the modifier screens (whether the gene is a suppressor, enhancer, or non-modifier), experimental details (mutated genes,
method for gene expression modulation, phenotype observation, etc.), and a link to the original article in which the experiment was
described (PubMed).
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genes that contain the keyword ‘nup4’ are suggested.
Selecting the D. melanogaster Nup44A gene from the
suggestions will open this gene’s page directly. On the
other hand, entering ‘nup4’ and clicking the ‘Search’ but-
ton will list all genes that contain the keyword and show
respective experimental record summaries. The user can
open the Nup44A gene page by clicking on the gene
name Nup44A of the listed genes.
Ontology-based search for related genes
The keyword-based search directs the user to a specific
gene, but this feature is not appropriate when searchingfor functionally related genes, e.g. searching for genes
involved in the cell cycle. For such a relation-based search,
we provide the ontology-based search. To use the
ontology-based search, the user has to type a GO term or
GO ID in the search box. Just like the keyword search,
suggestions will pop up and the user can select one of the
suggested GO terms. Then, NeuroGeM searches for not
only genes with the user-specified GO term but also genes
with a related (child) term. This ontology-based search
will assist users in the identification of modifiers that are
associated with specific cellular functions or processes.
For instance, as shown in Additional file 3: Figure S2,
the query of ‘cell cycle (GO:0007049)’ in D. melanogaster
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out of 656 genes have been evaluated experimentally,
and 256 out of 622 genes have been identified as modi-
fiers. Drosophila’s Nup44A gene is also shown in the
gene list since Nup44A has GO annotations for regula-
tion of mitotic cell cycle (GO:0007346) and regulation of
meiotic cell cycle (GO:0051445), which are child terms of
cell cycle. Clicking on the name of Nup44A will direct
the user to Nup44A genetic modifier information page.
Genetic modifier information
At the end of each search, NeuroGeM directs users to
the genetic modifier information page of a specific gene.
As an example, the genetic modifier information page of
the Drosophila gene Nup44A (FBgn0033247) is shown
in Figures 2 and 3. Terms and definitions used in genetic
modifier information pages are listed in Table 2.
At the top of the genetic modifier information page
(Figure 2a), the number of experimental records that are
available in NeuroGeM for a specific gene and its homo-
logs are reported (record summary) for each experimen-
tal scale (“L” stands for LT, “H2” for secondary HT, and
“H1” for primary HT). If experimental data that identi-
fies a specific gene as a modifier has been entered in
NeuroGeM, this fact is highlighted in red, light red if it
is only one HT experiment, and dark red if it is at least
two HT experiments or at least one LT experiment.
Similarly, records that report that a gene is a non-
modifier are colored in light and dark blue. For example,
there are currently two records in NeuroGeM for
Nup44A indicating that Nup44A (FBgn0033247) is a
non-modifier in HD, one based on a LT and one on a
primary HT experiment. In addition, there are two re-
cords of LT experiments indicating that Nup44A is a
modifier in SCA1. By clicking on a specific record in the
“record summary” at the top of the page (e.g. “2 0 0”
under the column header “L H2 H1” for Nup44A and
SCA1), the user is immediately guided to the details of
that entry (Figure 3).
Below the report summary, detailed information of the
gene is displayed on the left side (Figure 2b), including
synonyms, alternative gene names, and IDs used in other
databases as well as GO annotations. On the right side
(Figure 2c), NeuroGeM displays the protein-protein
interaction sub-network around the gene, in which inter-
acting proteins are colored by the type and result of ex-
periments that tested them as modifiers. Specifically, the
left half of each node (protein) is colored according to
the evidence for it being a modifier. The right half of
each node is colored according to the evidence for it be-
ing a non-modifier. The same coloring scheme as for the
record summary is used. Importantly, the protein-
protein interaction network and the coloring are
organism- and disease-specific (coloring by differentdiseases can be selected below the network). Users can
navigate to other genetic modifier information pages by
clicking on the corresponding nodes. Figure 2c shows
the protein-protein interaction sub-network of Nup44A
colored according to the results of screens for modifiers
of HD in Drosophila. A look at the network immediately
reveals that Nup44A, Nup75, and Rae1 were identified
as non-modifiers, while Nup107 was identified as modi-
fier of HD in Drosophila. By contrast, SmB, SmD1,
Cbp20, and Nup154 were identified as modifiers in some
experiments but not in others.
In the next section of the genetic modifier information
page, experimental details are displayed (Figure 3). Ex-
periments are categorized by the disease model, and the
number of experimental records for each disease model
is shown with respect to experimental scale by using the
same coloring scheme as for the report summary. The
reported experimental details include: (i) type of modifi-
cation; indicates whether the experiment found the gene
to be a suppressor, enhancer, or non-modifier, (ii) mode
of action; reports whether the queried gene modified ag-
gregation size/number or changed disease symptoms,
(iii) disease induction; denotes which (mutant) gene was
used to cause disease symptoms, and shows the mutant
gene and its expression cassette information, (iv) modu-
lation method; denotes how the expression of the quer-
ied gene was modulated (e.g. over-expressed, knocked
out, repressed by RNAi), (v) experimental scale; denotes
the scale of performed experiments (LT, primary HT,
secondary HT; secondary HT stands for experiments to
confirm the results obtained from primary HT experi-
ments), (vi) measurement; denotes what was quantified
to identify a modifier and (vii) cell type; denotes the cell
lines or stocks utilized in the experiment. For instance,
Nup44A was tested as modifier in a Drosophila model of
SCA1 that was created by expressing Ataxin-1 with a
polyQ expansion of 82 (Figure 3). The impact of the
overexpression of Nup44A on the disease model was
quantified based on changes in the severity of an eye
phenotype. Nup44A was categorized as a suppressor, in-
dicating that the over-expression of the Nup44A gene al-
leviated the severity of the eye phenotype.
Below the experimental details of a specific gene, its
homologous genes are displayed with genetic informa-
tion, protein interaction sub-network, and experimental
details if available.
Search for orthologs of human and mouse genes
The current version of NeuroGeM does not contain any
genetic modifiers in human and mouse (to be included
at a later stage). Nevertheless, researchers studying gen-
etic modifiers of NDs in the three model organisms are
likely to be interested in the homologous genes of the
modifiers in higher organisms such as human and
Table 2 Terms used in NeuroGeM
Terms Values Meaning
Organism D. melanogaster Three model organisms
C. elegans
S. cerevisiae
Gene ID FBgn———— Primary IDs used in the respective genome databases (FlyBase, WormBase,
and SGD). These IDs are also used as primary IDs in NeuroGeM.
W——————
S———————
Type of modification Suppressor Suppressors are those genes that alleviate disease pathology or slow disease
progression when over-expressed, and those that aggravate disease pathology
or accelerate disease progression when down-regulated or deleted. Enhancers
are those genes that alleviate disease pathology when down-regulated, and
those that aggravate pathology when over-expressed. Non-modifiers have no
effect on disease progression.
Enhancer
Non-modifier
Mode of action Toxicity modification Toxicity modifiers are those genes that change disease pathology. Aggregation
modifiers are those genes that change the size or number of protein aggregates.
Aggregation modification
Disease model Alzheimer’s disease (AD) ND models compiled in the current version of NeuroGeM. We divided AD into
the subtypes ADTau and ADAβ according to the gene used to induce the disease
phenotype (mutant Tau protein and Aβ42, respectively).Huntington’s disease (HD)
Parkinson’s disease (PD)
Spinocerebellar ataxia type 1 (SCA1)
Spinocerebellar ataxia type 3 (SCA3)
Spinocerebellar ataxia type 7 (SCA7)
Amyotrophic lateral sclerosis (ALS)
PolyQ disease (PolyQ)
Disease induction Various This field contains expression cassette information described in the literature
including promoter and disease-causing gene (e.g. polyQ stretch length).
Disease-causing mutant proteins compiled in NeuroGeM are Aβ and tau protein
for AD, SOD1 for ALS, huntingtin for HD, α-synuclein for PD, Ataxin-1 for SCA1,
Ataxin-3 (MJD) for SCA3, Ataxin-7 for SCA7 and polyQ stretches for the PolyQ
disease model.
Modulation method Overexpression This field describes whether the expression level of the target gene increased
(overexpression or gain-of-function) or decreased (knockdown, knockout, or




Experimental scale Primary high-throughput This field describes the scale of the experiments. Experiments that were not high-
throughput (HT) were assigned as low-throughput (LT). Experiments performed in
primary screens were assigned as Primary high-throughput. Experiments to confirm




Measurement Various This field describes how the change of pathology was evaluated. For example,
change in the eye phenotype is a common readout in D. melanogaster, and cell
growth rate is a common readout in S. cerevisiae.
Cell type Various This field briefly describes what cell lines and organs were utilized to carry out the
experiment.
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tion from the EMBL and HGNC databases and mouse
genome information from the EMBL and MGI databases.
The user can search for human and mouse genes using
their gene names or EMBL IDs, and then obtain not only
information on the queried genes but also information ontheir homologous genes in D. melanogaster, C. elegans,
and S. cerevisiae. For example, Drosophila’s Nup44A gene
and its homologous genes in other species are listed in
Figure 2a and the information on those genes is displayed
at the bottom of the Nup44A gene page (omitted in
Figures 2 and 3). The user can also search for human and
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(Seh1l and SEH1L) or EMBL IDs (ENSMUSG00000079614
and ENSG00000085415) in the unified search box.
Applications of data in NeuroGeM
In order to demonstrate the broad applicability of Neuro-
GeM and how it can provide new understanding, we per-
formed a variety of meta-analyses using the genetic
modifiers data from NeuroGeM. In this section, the
results of the meta-analyses are discussed briefly. The de-
tailed methods, results and discussion for the meta-
analyses are available in the Additional file 1. Due to the
abundance of both HT and LT experimental data from
D. melanogaster, mainly results obtained from the meta-
analysis of genetic modifiers of D. melanogaster are pre-
sented here. Results from the analysis of genetic modifiers
in other model organism as well as the comparison of
modifiers in all three model organisms are available in
Additional file 1.
i) NeuroGeM can be used to identify biological
processes that are enriched within genetic modifiers
in a specific disease or in groups of diseases. Genes
with annotations for these processes can beFigure 4 Compilation of meta-analysis results. (a) Functional classification
(b) (Left) Correlation analysis of modifiers and non-modifiers between diseases. P
by a color matrix ranging from −1 (inverse correlation, red), via 0 (no correla
SCA3 and ADTau were further analyzed to see which functional categories ar
identified as modifiers of several diseases in D. melanogaster. Red and grey d
modifier and non-modifier, respectively (see Additional file 1: Figure S7 for f
annotation as in (c) is used here (see Additional file 1: Figure S8 for full list).
and PD modifiers in C. elegans with respect to the mode of action of the mo
aggregation and toxicity modifiers. (f) Identification of modifiers and non-m
models in D. melanogaster. Each line refers to one gene and each green dot
stretch. If dots are in the purple and green region, it means the gene has be
Additional file 1 for details of meta-analysis.prioritized for testing in other model organisms or
for drug screenings. A meta-analysis of the data
deposited in NeuroGeM revealed that modifiers
across species are often involved in protein folding
(Figure 4a). However, they account for only 3% of all
genetic modifiers. The analysis revealed that modifiers
are equally often involved in cell cycle and splicing,
accounting for 7% and 3% of all genetic modifiers,
respectively. This analysis result suggests that
researchers expecting to discover more genetic
modifiers should focus their efforts also on genes
involved in cell cycle and splicing, biological processes
that are also often enriched in modifiers. As shown in
Figure 4b, a correlation analysis of modifiers between
diseases revealed that polyQ diseases (HD, generic
PolyQ, SCA1, SCA3, and SCA7 in Figure 4b) share
many genetic modifiers and non-modifiers which
are not seen in AD models, which is consistent with
a previous report [21]. Specifically, a strong
anti-correlation is observed when comparing the
modifiers and non-modifiers of ADAβ and SCA3.
Many SCA3-specific genetic modifiers are involved in
protein folding and splicing [22,23], while ADAβ-specific
modifiers are involved in protein synthesis [24].of genetic modifiers and their enrichments represented by p-values.
airwise correlations (Matthew’s correlation coefficient) are represented
tion, yellow), to 1 (high correlation, green). (Right) Modifiers in
e enriched among these genetic modifiers. (c) List of genes
enote the number of diseases in which a gene is identified as a
ull list). (d) List of disease-specific genetic modifiers. The same color
(e) Enrichment analysis results of HD modifiers in D. melanogaster
difiers. Tox, toxicity modifiers; Agg, aggregation modifiers; Both,
odifiers depending on the length of the polyQ stretch in HD
refers to one experiment with a specific length of the polyQ
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processes can be prioritized in future screens to
confirm these trends and elucidate their mechanisms.
See Additional file 1.
i) NeuroGeM allows easy identification (by non
computational experts) of genes that modify the
neurodegenerative toxicity in several ND models.
Hence, cross-disease comparisons can identify
potential generic modifiers that then can be tested
experimentally in other disease models in other
organisms (rodents) or compared to human genetic
data. A first search for generic modifiers revealed
that the genes DnaJ-1, thread, Atx2, and mub are
modifiers in 5 out of 7 ND models in D. melanogaster
(Figure 4c). Interestingly, DNAJB4 and BIRC3, the
mammalian orthologs of DnaJ-1 and thread, have
recently been shown to reduce neuronal cell death
when up-regulated in multiple mammalian NDble 3 Genes that are toxicity and aggregation modifiers in D
H. sapiens and M. musculus1
melanogaster genes D. melanogaster
ND models2
Ref H. s




read ADTau, HD, SCA1,
SCA3, SCA7
[21,32,41,42] BIRC
x2 ADTau, HD, SCA1,
SCA3, SCA7
[21,41,42,46] Atx
c70-3 HD, SCA1, SCA7 [32,42] HSP
c70Cb ADTau, HD, SCA3 [5,54,55] HSP
HSP
d3 HD, SCA1, SCA7 [34,42,58] HD
-3-3epsilon HD, SCA1 [66,67] YW
5537 HD [74] UPR
f HD, SCA3 [75] Hsf2
Hsfy
pped-A HD, SCA3, SCA7 [42,54,55] TRR
c61alpha HD, SCA3 [81] Sec
p160 HD, SCA3 [55,74] Nup
1109 HD [74] WD
ap HD [66] NAP
t3 HD [74] SUM
SUM
ef2 HD [66] MEF
MEF
ic HD [98] PFN
t1 HD [74] PSM
n3A HD, SCA1, SCA3 [5,32,34] Sin3
eb ADTau, HD [74,104] Rhe
rthologs were obtained from NeuroGeM in which protein homolog groups of NCBI
isease models in which the genes were identified as modifiers.
tudies in which the mammalian orthologs were identified as modifiers.models (see Additional file 1). Moreover, Atx2 has
recently also been associated with an increased risk
for ALS [25]. Further experiments are necessary to
confirm this hypothesis that DnaJ-1, thread, Atx2,
and mub are generic modifiers.
ii) Equally, NeuroGeM facilitates the identification of
genes that only affect the phenotype of specific NDs.
Though all NDs are caused by aggregates, they
definitely show different pathophysiology. In this
regard, genes capable of modulating disease
phenotype only in a specific ND give us hints to
understand the difference in disease progression. For
instance, modifiers currently confined to ADTau in
D. melanogaster include sgg and par-1 (Figure 4d).
This finding is consistent with the specific importance
of hyper-phosphorylation of the tau protein in AD,
which is a process that may be accelerated by par-1
and sgg [26,27]. In S. cerevisiae, modifiers are enriched. melanogaster and their orthologs






2, BIRC3 Birc2, Birc3 [43-45]







AC1, HDAC2 Hdac1, Hdac2 [59-65]
HAZ, YWHAB, YWHAE Ywhaz, Ywhab, Ywhae [67-73]
T Uprt N/A
, Hsf4, Hsfx1, Hsfx2,
1, Hsfy2, Hsf5




61A1, Sec61A2 Sec61a1, Sec61a2 [82,83]
160 NUP160 [84-86]
R33(WDC146) Wdr33 (Wdc146) N/A
A, NAPB Napa, Napb N/A
O1, SUMO2, SUMO3,
O4








A, Sin3B Sin3a, Sin3b [103]
b, RhebL1 Rheb, Rhebl1 [105,106]
HomoloGene and InParanoid were integrated.
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PPR1, MBP1, SRO9, SLF1, and SLS1), protein folding
in HD (HSP26, HSP42 and APJ1), and transport in PD
(FUN26, YCK3, and GOS1), which is consistent with
recent results (Additional file 1).
v) The database can help get new insights into the
mechanism of disease modulation. In NeuroGeM,
each modifier is classified as toxicity modifier and/or
an aggregation modifier: toxicity modifiers change
disease phenotype (eye development, motility, etc.),
and aggregation modifiers primarily affect aggregate
size or number. As shown in Figure 4e, toxicity
modifiers are enriched in cell cycle, cytoskeleton,
signaling, and protein folding categories; these
modifiers are involved in cellular pathways that
modulate the level of tolerance to the stress caused
by the aggregates and ultimately lead to phenotypic
changes. On the other hand, aggregation modifiers
are enriched in splicing, proteolysis, and protein
folding, which are the processes directly or indirectly
associated with aggregate formation and elimination.
Interestingly, modifiers belonging to both groups are
only enriched in protein folding. This functional
category includes protein quality control, which is a
network of cellular processes that in an orchestrated
manner works against protein misfolding and
aggregation. Therefore, proteins involved in protein
folding would be prime therapeutic targets, since
they are able to resolve the problem of aggregate
formation, and are involved in cellular processes that
can increase the tolerance to the cellular stress
caused by protein aggregation [28,29]. Moreover,
these proteins may play a key role in the
pathophysiology of many NDs due to their dual
effect. In order to test this hypothesis, we identified
Drosophila modifiers that are both aggregation andFigure 5 Ontology-based search results of “anti-apoptosis”. (a) Genes ret
“anti-apoptosis” (GO:0006916). Genes annotated with anti-apoptosis or its chil
genes. Proteins that are directly interacting with the discovered modifiers are
green nodes, genes with literature evidence (not yet entered into NeuroGeMtoxicity modifiers. We found that many of them are
indeed able to modulate neurodegeneration in
several different disease models (see Table 3 and
Additional file 1). Interestingly, the list includes
three of the previously identified generic modifiers;
DnaJ-1, thread and Atx2. Next, we tested whether
this is true across species, i.e. also for higher
organisms. We identified human and mouse
orthologs of the Drosophila aggregation and toxicity
modifiers by using the feature of NeuroGeM. A
careful literature search confirmed that for most of
the mammalian orthologs of these modifiers there
exists experimental evidence that they modify the
phenotype of several ND models in mammalian cells
(see Table 3 and Additional file 1 for details about the
orthologs).
) NeuroGeM allows assessing the effect of
experimental conditions on the consistency and
reliability of the identified modifiers. The results of
different screens for genetic modifiers are often
inconsistent because of the use of different
experimental set-ups. NeuroGeM enables the user to
infer the best experimental conditions for consistent
identification of modifiers. As an example, we
investigated the effect of polyQ stretch length on
modifier identification in HDmodels ofD.melanogaster.
In Figure 4f, each line refers to one gene identified
as a modifier or non-modifier in secondary HT or
LT experiments in HD models with different polyQ
lengths, and each green dot on the line refers to the
identification result at a specific polyQ length.
Figure 4f suggests some genes were not identified as
modifiers in HD models with a polyQ length of 40
(which is above the canonical threshold of 35), but
were then identified as modifier in models with a
polyQ length of 60. Hence, this analysis suggestsrieved from NeuroGeM using the Ontology-based search for
d terms are listed. (b) Protein interaction clusters of the retrieved
shown: red nodes, known modifiers; white nodes, untested genes;
) for being modifiers.
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http://www.biomedcentral.com/1755-8794/6/52that HD models with polyQ > 60 may provide more
sensitivity (see Additional file 1 for details).
i) Most importantly, NeuroGeM facilitates the
identification of new, so far untested modifiers.
Mapping of genes on the protein interaction
networks allows identification of new, untested
genetic modifiers based on guilt-by-association. We
illustrate this idea on genes involved in anti-apoptosis
(GO:0006916). We first obtained 24 anti-apoptotic
proteins in D. melanogaster (Figure 5a), and among
these genes debcl, Buffy, and thread are interconnected
with each other in the protein network (Figure 5b). In
order to investigate whether genes interacting with
these anti-apoptotic modifiers could also be modifiers,
we extended the sub-network by adding proteins that
interact with the three proteins. This extension can be
easily done, as NeuroGeM allows the user to
navigate from one gene to another by clicking on a
node in a network. The newly added genes are
highly interconnected with each other. Detailed
literature surveys of the genes connected to debcl,
Buffy, and thread revealed that 5 out of 15 interactors
(marked in green in Figure 5b) are modifiers or at least
highly related to disease progression. For example, one
of the interactors is Ark; inactivation of Ark
(FBgn0263864), a key regulator of apoptosis, is known
to suppress formation and ubiquitination of polyQ
aggregates [107] (Please see Additional file 1 for the
details about the other four interactors and potential
modifiers). Hence, the search tools of NeuroGeM will
facilitate the identification of new modifiers that are
involved in specific pathways or cellular processes.Conclusion
Here we report, to the best of our knowledge, the first
database (NeuroGeM) of genetic modifiers of NDs. Neuro-
GeM provides a platform for searching modifiers, retrieving
experimental conditions used for modifier identifica-
tion, interpreting the roles of a queried modifier in the
context of the protein interaction network, and expand-
ing knowledge in one organism to other organisms
through homologous genes. Therefore, NeuroGeM al-
lows users to evaluate their hypotheses and develop new
research directions. Furthermore, NeuroGeM provides
all information, including gene information, protein in-
teractions, experimental set-ups, etc. in down-loadable
files, which will facilitate other computational analyses
of modifiers similar to the meta-analysis presented in
this work. Consequently, NeuroGeM will assist scien-
tists immensely in their search for the pathophysio-
logical mechanisms underlying NDs by providing the
first compendium that catalogues and cross-links their
genetic modifiers.Availability and requirements
NeuroGeM can be accessed from a web browser and is
available at http://chibi.ubc.ca/neurogem.
Additional files
Additional file 1: A text with figures addressing the meta-analysis
results in detail mentioned in the main text.
Additional file 2: Figure S1. A figure to illustrate a categorical search.
Additional file 3: Figure S2. A figure to illustrate an ontology-based
search.
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